# Convergent Ventures

> Convergent Ventures is a VC fund backing Biotechnology and Artificial Intelligence. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 5
- Last investment: May 2026
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/convergent-ventures-llc/about/
- Website: https://convergentvc.com/

Convergent Ventures is a VC fund in San Francisco focused on Biotechnology and Artificial Intelligence. Convergent Ventures operates as a ventures capital firm. Convergent Ventures actively scout, invest in, and nurture early-stage teams whose passion and product lie at that intersection.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Artificial Intelligence | 2 | 40% |
| Military | 1 | 20% |
| Automotive | 1 | 20% |
| Health Care | 1 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Seed | 1 | 20% |
| Series A | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 40% |
| Canada | 1 | 20% |
| Germany | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dandelion Health AI | Dandelion Health AI develops a clinical data and artificial intelligence platform that enables life sciences companies and researchers to analyze real-world patient data and accelerate drug development and clinical research. The company provides a precision medicine platform that aggregates multimodal healthcare data, including clinical notes,medical images, and physiological waveforms, into a unified dataset representing patient journeys over time. Its platform applies validated AI models to transform large volumes of unstructured clinical data into structured, research-ready datasets, allowing researchers to uncover insights into disease progression, treatment effectiveness, and patient outcomes. This capability enables more comprehensive analysis compared to traditional datasets that rely primarily on structured records such as claims or diagnostic codes. | $14M | Series A | May 05, 2026 |  |
| Profluent Bio | Profluent Bio is an AI-first protein design company that designs novel, optimal proteins that bypass existing barriers in industry. | $106M | Series B | Nov 19, 2025 |  |
| FibreCoat | FibreCoat GmbH produces thermoplastic-coated glass fibres for use in fibre composites on rented glass fibre drawing machines. Direct coating enables new process steps, lower costs and cycle times while at the same time improving technical specifications. The target markets are the automotive and consumer sectors. | $21M | Series B | Dec 04, 2024 |  |
| NanoVation Therapeutics | NanoVation Therapeutics provides technologies utilizing lipid nanoparticles for the safe and efficient delivery of nucleic acid tissues. |  | Seed | Nov 19, 2024 |  |
| Profluent Bio | Profluent Bio is an AI-first protein design company that designs novel, optimal proteins that bypass existing barriers in industry. | $35M | Venture - Series Unknown | Mar 21, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [Spark Capital](https://shizune.co/investors/profile/spark-capital) — VC Fund, 3 deals together
- [212 NexT](https://shizune.co/investors/profile/212-next) — VC Fund, 2 deals together
- [Air Street Capital](https://shizune.co/investors/profile/air-street-capital) — VC Fund, 2 deals together
- [AIX Ventures](https://shizune.co/investors/profile/aix-ventures) — VC Fund, 2 deals together
- [Insight Partners](https://shizune.co/investors/profile/insight-partners) — VC Fund, 2 deals together
- [Altimeter Capital](https://shizune.co/investors/profile/altimeter-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Convergent Ventures invest in?

Convergent Ventures invests primarily in Biotechnology, Artificial Intelligence and Military startups, most often at Series B and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Convergent Ventures last invest?

The most recent investment recorded for Convergent Ventures closed in May 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co